Zhejiang Orient Gene Biotech Co (SHSE:688298) Beneish M-Score: -2.90 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688298 Zhejiang Orient Gene Biotech Co Ltd SHSE:688298
51 GF Score
Price ¥17.87
GF Value ¥30.81
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Zhejiang Orient Gene Biotech Co Beneish M-Score?

Zhejiang Orient Gene Biotech Co SHSE:688298 -3.51% 51 Beneish M-Score is -2.90 as of Jul. 26, 2026. GuruFocus rates SHSE:688298 with a GF Score™ of 51/100 and a GF Value™ of ¥30.81 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 763 Medical Devices & Instruments companies, Zhejiang Orient Gene Biotech Co ranks better than 73.39% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.9 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zhejiang Orient Gene Biotech Co's Beneish M-Score or its related term are showing as below:

SHSE:688298' s Beneish M-Score Range Over the Past 10 Years
Min: -2.95   Med: -1.58   Max: 8.07
Current: -2.9

During the past 10 years, the highest Beneish M-Score of Zhejiang Orient Gene Biotech Co was 8.07. The lowest was -2.95. And the median was -1.58.


Zhejiang Orient Gene Biotech Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Zhejiang Orient Gene Biotech Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Orient Gene Biotech Co Beneish M-Score Chart

Zhejiang Orient Gene Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -2.86 1.99 -1.97 -2.87

Zhejiang Orient Gene Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 -2.64 -2.64 -2.87 -2.90

SHSE:688298 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Zhejiang Orient Gene Biotech Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Orient Gene Biotech Co Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Orient Gene Biotech Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Orient Gene Biotech Co's Beneish M-Score falls into.


SHSE:688298
51GF Score
Zhejiang Orient Gene Biotech Co Ltd SHSE:688298
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Orient Gene Biotech Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zhejiang Orient Gene Biotech Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7487+0.528 * 0.6975+0.404 * 1.02+0.892 * 1.2088+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8933+4.679 * -0.055602-0.327 * 0.9417
=-2.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥189 Mil.
Revenue was 256.265 + 275.568 + 268.732 + 211.128 = ¥1,012 Mil.
Gross Profit was 109.922 + 106.757 + 128.088 + 99.117 = ¥444 Mil.
Total Current Assets was ¥3,038 Mil.
Total Assets was ¥6,893 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,622 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥229 Mil.
Total Current Liabilities was ¥802 Mil.
Long-Term Debt & Capital Lease Obligation was ¥70 Mil.
Net Income was -93.843 + -360.966 + -49.534 + -47.645 = ¥-552 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -29.109 + -39.266 + -31.362 + -68.982 = ¥-169 Mil.
Total Receivables was ¥209 Mil.
Revenue was 191.952 + 170.302 + 239.379 + 235.313 = ¥837 Mil.
Gross Profit was 52.518 + 34.652 + 79.2 + 89.757 = ¥256 Mil.
Total Current Assets was ¥3,584 Mil.
Total Assets was ¥7,759 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,815 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥212 Mil.
Total Current Liabilities was ¥887 Mil.
Long-Term Debt & Capital Lease Obligation was ¥156 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(189.499 / 1011.693) / (209.383 / 836.946)
=0.187309 / 0.250175
=0.7487

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(256.127 / 836.946) / (443.884 / 1011.693)
=0.306026 / 0.438754
=0.6975

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3038.343 + 2622.091) / 6893.051) / (1 - (3583.909 + 2814.923) / 7759.162)
=0.17882 / 0.175319
=1.02

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1011.693 / 836.946
=1.2088

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2814.923)) / (0 / (0 + 2622.091))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(229.279 / 1011.693) / (212.334 / 836.946)
=0.226629 / 0.253701
=0.8933

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((69.696 + 802.319) / 6893.051) / ((155.632 + 886.725) / 7759.162)
=0.126506 / 0.134339
=0.9417

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-551.988 - 0 - -168.719) / 6893.051
=-0.055602

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zhejiang Orient Gene Biotech Co has a M-score of -2.90 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.90 mean?
Zhejiang Orient Gene Biotech Co (SHSE:688298) has a Beneish M-Score of -2.90 as of Jul. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. According to the industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #203 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 26.6%.
Is Zhejiang Orient Gene Biotech Co's Beneish M-Score too high?
Zhejiang Orient Gene Biotech Co's current Beneish M-Score is -2.90. Based on the distribution chart, Zhejiang Orient Gene Biotech Co ranks #203 out of 763 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zhejiang Orient Gene Biotech Co has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Orient Gene Biotech Co's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #203 out of 763 companies for Beneish M-Score. This puts Zhejiang Orient Gene Biotech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. Zhejiang Orient Gene Biotech Co's current Beneish M-Score is -2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Orient Gene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co (SHSE:688298) is currently considered Possible Value Trap. The stock's GF Value™ is ¥30.81, compared to a current price of ¥17.87 — trading 42% below its estimated fair value. The current Beneish M-Score is -2.90. Zhejiang Orient Gene Biotech Co's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Zhejiang Orient Gene Biotech Co (SHSE:688298), the current Beneish M-Score is -2.90 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Orient Gene Biotech Co (SHSE:688298) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co stock appears to be undervalued. The current stock price of ¥17.87 is trading 42% below its estimated GF Value™ of ¥30.81. GuruFocus considers Zhejiang Orient Gene Biotech Co to be Possible Value Trap.

Key valuation signals for SHSE:688298:

  • Beneish M-Score: -2.90
  • GF Value™: ¥30.81 vs. price of ¥17.87 (42% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688298 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Orient Gene Biotech Co Business Description

Address 3787 East Section of Yangguang Avenue, Dipu Street, Anji County, Zhejiang Province, Huzhou, CHN, 313300
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
51GF Score

Get the complete analysis for SHSE:688298

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.87
Price
¥30.81
GF Value